Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2015-10-19
2016-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The sample will be the result of a non-probabilistic sampling process, calculated based on the magnitude of the effect of the main variable (distance traveled) after the use of NIV therapy, obtained in a pilot study. In addition, this protocol was aproved by the institution's Ethics Committee on Human Research (CAAE: 49324415.0.000.5537).
Experimental procedure The experimental protocol will occur in three visits, one per day, with a minimum interval of 48 hours between them. On the first visit, the volunteers will undergo a screening that consists of clinical evaluation (assessment sheet) and cognitive (Leganéscognitive test), as well as evaluation of lung function (spirometry) and QoL (Minnesota Living with Heart Failure Questionnaire). Next, the Shuttlel Walking Test (SWT) control (T-Co) will be performed, without previous use of NIV, in order to determine the distance traveled and other physiological variables in the absence of interventions. Finally, during the initial visit, a preliminary NIV session will be held to adjust the interface and adapt the volunteer to the therapy.
At each subsequent visit, volunteers will perform a SWT immediately after 30 minutes of NIV, one day in Bi-level mode and one in CPAP mode, following a randomized sequence. Thus, all volunteers will perform one SWT after CPAP (T-CP) and one SWT after Bi-level (T-Bi). In the experiment, the CPAP pressure will be maintained at 6 cmH2O, while at the Bi-level an expiratory pressure (EPAP) of 6 cmH2O and an inspiratory pressure (IPAP) of 12 cmH2O will be defined.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
First intervention
The subjects did a shuttle walk test without any previous intervention.
Shuttle walk test
A shuttle walk test was performed without any previous intervention.
Second intervention
Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
Noninvasive ventilation (CPAP)
After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Third intervention
Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
Noninvasive ventilation (Bi-pap)
After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shuttle walk test
A shuttle walk test was performed without any previous intervention.
Noninvasive ventilation (Bi-pap)
After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Noninvasive ventilation (CPAP)
After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Present functional class II and III (New York Heart Association);
3. Present left ventricular ejection fraction (LVEF) ≤ 50%;
4. Have not suffered myocardial infarction in the last three months;
5. No previous diagnosis of chronic obstructive pulmonary disease (FEV1 / FVC ratio\> 70% in spirometry);
6. Do not be a smoker;
7. Not being pregnant;
8. Does not present any clinical disease or restriction of osteomioarticular or neurological origin that prevents / limits the carrying out of the proposed tests;
9. Integral cognitive functions, which were evaluated by the cognitive test of Leganés - PCL
Exclusion Criteria
2. Acute atrial fibrillation or total atrioventricular block;
3. Systemic blood pressure (AP) at uncontrolled rest (≥ 180/110 mmHg or ≤80 / 40mmHg);
4. Resting heart rate (HR) ≤ 40 bpm or ≥ 120 bpm;
5. Need for dialysis;
6. Use of bronchodilator;
7. Respiratory rate (RF) at rest ≥ 35 rpm;
8. Frequent vomiting;
9. Intolerance to NIV;
10. infection or fever.
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Patri-cia Angelica de Miranda Silva Nogueira
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Patri-cia Angelica de Miranda Silva Nogueira
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrícia Nogueira, PhD
Role: PRINCIPAL_INVESTIGATOR
college professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1a2b3c4d
Identifier Type: -
Identifier Source: org_study_id